32 results about "Isopropyl formate" patented technology

The present invention relates to 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methyl-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, pharmaceutically acceptable salts, solvates and hydrates thereof that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

The present invention relates to 4-[5-Methoxy-6-(2-methyl-6-[1,2,4]triazol-1-yl-pyridin-3-ylamino)-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, pharmaceutically acceptable salts, solvates and hydrates thereof that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

The oxidation of isobutyraldehyde produces isobutyric acid and byproducts, such as isopropyl formate. A process of reducing the isopropyl formate byproduct and other byproducts in the oxidation of isobutyraldehyde is described. The process uses a carbonyl compound, such as acetone, to reduce byproduct levels in the resulting product. Process for use of static mixers in oxidation reactions of aldehydes are also provided.

The oxidation of isobutyraldehyde produces isobutyric acid and byproducts, such as isopropyl formate. A method of reducing the isopropyl formate byproduct in the oxidation of isobutyraldehyde is described. The method uses a co-solvent, such as acetone, to the isobutyraldehyde feed to increase both the selectivity of the reaction to isobutyric acid and the production rate of isobutyric acid so that the isopropyl formate byproduct is significantly reduced.

The invention relates to a preparation method of azelnidipine, belongs to the field of medicines and opens up a new way for synthesizing dihydropyridine calcium antagonists. With cyanoacetic acid as a raw material, the method comprises the following sequential steps: synthesizing isopropyl 2-amino-3-carboxyl-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-5-formate through a Pinner reaction and a Hantzsch reaction; and performing DCC dehydration esterification with 1-diphenylmethyl-3-hydroxyl azetidine hydrochloride to obtain a crude product of azelnidipine; and performing further crystal transformation to obtain alpha-crystal type azelnidipine.

Pesticide composition comprising as active ingredients at least one specific imidazole compound and at least one fungicide, wherein the fungicide is selected from (S)-5-methyl-2-methylthio-5- Phenyl-3-phenylamino-3,5-dihydrimidazol-4-one, 2-methyl-1-[(1-p-tolylethyl)carbamoyl]-(S)-propylamino Isopropyl formate, 3,5-dichloro-N-(3-chloro-1-ethyl-1-methyl-2-oxopropyl)-4-methylbenzamide and N-(α- Cyano-2-thienyl)-4-ethyl-2-(ethylamino)-5-thiazolecarbamoyl.

The invention discloses a preparation method of sodium salt of pravastatin, which comprises the following steps: adding inorganic alkaline or organic alkaline containing sodium ions as positive ions into organic solution containing the pravastatin until pH is more than 7 and obtaining sodium pravastatin; the organic solution containing the pravastatin comprises the pravastatin and first solvent, wherein the first solvent is selected from one or a plurality of methyl formate, n-propyl formate, isopropyl formate, n-butyl formate, methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate, sec-butyl acetate, isobutyl acetate and tert-butyl acetate.

The present invention relates to 4-[5-methyl-6-(2-methyl-pyridin-3-yloxy)-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, pharmaceutically acceptable salts, solvates and hydrates thereof that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

The invention discloses a pharmaceutical composition for treating type 2 diabetes. The pharmaceutical composition contains a therapeutically-effective amount of 1'-(1H-indazol-5-carbonyl)-1-isopropyl-4,6-dihydrospiro[indazol-5,4'-piperidine]-7(1H)-one and a therapeutically-effective amount of 4-[5-cyano-4-({2-fluoro-4-[1-(2-hydroxyethyl)-1H-tetrazol-5-yl]phenoxy}methyl)-1H-pyrazol-1-yl]piperidin-1-isopropyl formate which have the mass ratio of (3: 1) to (1: 3). The pharmaceutical composition can be used for effectively treating the type 2 diabetes.

The invention provides a battery foil rolling additive as well as a preparation method and application thereof. The battery foil rolling additive comprises the following components in percentage by mass: 10-20% of fatty acid ester, 15-30% of fatty alcohol, 45-65% of an adamantane compound and 0.1-5% of an extreme pressure additive, wherein the mass percentage content of dihydroxy adamantane isopropyl formate in the adamantane compound is 50 to 100 percent. According to the battery foil rolling additive, through matching of the components, especially the use of the adamantane compound with a specific molecular structure, the battery foil rolling additive has excellent lubricating performance, the surface quality of a rolled battery foil can be improved, the surface dyne value of the battery foil is increased, and the cost of a corona process is reduced; and meanwhile, the use of the battery foil rolling additive is beneficial to improving the dispersing performance and filtering efficiency of aluminum powder and improving the cleaning performance of a rolling mill.

The oxidation of isobutyraldehyde produces isobutyric acid and byproducts, such as isopropyl formate. A method of reducing the isopropyl formate byproduct in the oxidation of isobutyraldehyde is described. The method uses a co-solvent, such as acetone, to the isobutyraldehyde feed to increase both the selectivity of the reaction to isobutyric acid and the production rate of isobutyric acid so that the isopropyl formate byproduct is significantly reduced.

The oxidation of isobutyraldehyde produces isobutyric acid and byproducts, such as isopropyl formate. A process of reducing the isopropyl formate byproduct and other byproducts in the oxidation of isobutyraldehyde is described. The process uses a carbonyl compound, such as acetone, to reduce byproduct levels in the resulting product. Process for use of static mixers in oxidation reactions of aldehydes are also provided.

The invention discloses a SBS grafted type deodorizing mattress spray glue and a preparation method thereof, comprising the following components in parts by weight: 10-15 parts of methyl isobutyl ketone; 5-10 parts of isopropyl formate; aromatics 10-20 parts of environmentally friendly solvent oil; 15-25 parts of methylcyclohexane; 10-18 parts of SBS elastomer; 0.1-0.5 parts of BPO; 5-15 parts of MMA; 0-8 parts of BA; 1-3 parts of terminator; 10-15 parts of hydrogenated petroleum resin; 12-18 parts of hydrogenated rosin modified resin. The SBS grafted odor-free mattress spray glue of the present invention is colorless and transparent, has strong adhesive force, is resistant to yellowing, chalking, high temperature, oil, plasticizer, non-toxic, odorless and residue-free. It is an ideal glue spraying choice for mattress manufacturers. During the spraying process, the odor is small, and the film has no residual solvent and resin odor. The film is white and transparent. After sizing, it will not pollute light-colored mattress fabrics.

The invention discloses a method for determining the residual contents of 4-methyl piperazine-1-methyl formate, 4-methyl piperazine-1-ethyl formate and 4-methyl piperazine-1-isopropyl formate in zopiclone. The method comprises the following steps: preparing a contrast solution: precisely weighing a proper amount of methyl 4-methylpiperazine-1-formate, a proper amount of ethyl 4-methylpiperazine-1-formate and a proper amount of isopropyl 4-methylpiperazine-1-formate, putting the weighed materials into a volumetric flask, dissolving the weighed materials with acetonitrile, diluting the dissolved materials, and respectively preparing 125ng / mL limit concentration solutions; preparing a test sample solution: precisely weighing a proper amount of zopiclone test sample, placing the zopiclone test sample in a volumetric flask, dissolving and diluting the zopiclone test sample with acetonitrile, and preparing the zopiclone test sample into a 1mg / mL solution; and sample determination: respectively taking the test solution and the reference solution, directly injecting the test solution and the reference solution into a GCMS, recording a chromatogram, and calculating by peak areas according to an external standard method to obtain the contents of the 4-methylpiperazine-1-methyl formate, the 4-methylpiperazine-1-ethyl formate and the 4-methylpiperazine-1-isopropyl formate in the test solution.

The invention relates to the technical field of formic acid detection, and provides a detection method for formic acid in ant products. By selecting isopropanol as an extractant and a reactant to carry out an esterification reaction, the reaction is sufficient, and there is almost no interference between substances. Therefore, the accuracy of the test method is improved; at the same time, concentrated sulfuric acid and p-toluenesulfonic acid are used as the catalyst for the esterification reaction, which avoids the occurrence of side effects such as sulfonation, carbonization or polymerization due to the violent reaction when the concentrated sulfuric acid is used as the catalyst alone. The reaction occurs; the problem of poor selectivity of isopropyl formate and too slow reaction rate when single selection of p-toluenesulfonic acid is solved, through the coordinated use of the two, the reaction rate is moderate, and the transformation rate of the product isopropyl formate is simultaneously improved, This further improves the accuracy of the test results.